New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:17 EDTCYCCCyclacel receives U.S., EU patents for sapacitabine used with HDAC inhibitors
Cyclacel Pharmaceuticals announced the issuance of U.S. Patent No. U.S. 8,349,792 and European Patent No 2,101,790. Both patents include claims to combination treatment of sapacitabine, the Company's lead product candidate, with histone deacetylase, or HDAC, inhibitors. The patents provide exclusivity until June 2029 and December 2027 respectively.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2014
07:10 EDTCYCCCyclacel announces DSMB recommendation to continue Sapacitabine Phase 3 trial
Cyclacel Pharmaceuticals announced that the independent Data and Safety Monitoring Board, or DSMB, for the company's Phase 3 SEAMLESS study in acute myeloid leukemia, or AML, has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 317 randomized patients with at least 60 days of follow-up and noted that no safety or efficacy concerns were identified.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use